Doxorubicin binds in a cooperative manner to myocardial cells. Two binding sites.

abstract：:Cyclophosphamide demonstrates enhanced tumoricidal activity with decreased bone marrow toxicity when given on a divided-dose schedule in certain animal models. A total of 22 patients presenting with refractory metastatic cancer were treated in a phase I trial of continuous infusion of cyclophosphamide over 96 h. Granu...

journal_title：Cancer chemotherapy and pharmacology

authors： Eder JP,Elias AD,Ayash L,Wheeler CA,Shea TC,Schnipper LE,Frei E 3rd,Antman KH

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:The aim was to investigate in patients receiving doxorubicin whether any alteration in myocardial oxidative metabolism or blood flow as assessed by positron emission tomography (PET) could be observed either after the first dose of the drug, or during its chronic administration. METHODS:Six female non-heart-fa...

journal_title：Cancer chemotherapy and pharmacology

authors： Nony P,Guastalla JP,Rebattu P,Landais P,Lievre M,Bontemps L,Itti R,Beaune J,Andre-Fouet X,Janier M

更新日期：2000-01-01 00:00:00

abstract：PURPOSE:High-dose methotrexate (HD-MTX) is widely used in the treatment of non-Hodgkin lymphoma (NHL), but the pharmacokinetic properties of HD-MTX in Chinese adult patients with NHL have not yet been established through an approach that integrates genetic covariates. The purposes of this study were to identify both ph...

journal_title：Cancer chemotherapy and pharmacology

authors： Yang L,Wu H,de Winter BCM,Sheng CC,Qiu HQ,Cheng Y,Chen J,Zhao QL,Huang J,Jiao Z,Xie RX

更新日期：2020-05-01 00:00:00

abstract：PURPOSE:The plasma and cerebrospinal fluid (CSF) pharmacokinetics of the camptothecin analogs, 9-aminocamptothecin (9-AC) and irinotecan, were studied in a nonhuman primate model to determine their CSF penetration. METHODS:9-AC, 0.2 mg/kg (4 mg/m2) or 0.5 mg/kg (10 mg/m2), was infused intravenously over 15 min and iri...

journal_title：Cancer chemotherapy and pharmacology

authors： Blaney SM,Takimoto C,Murry DJ,Kuttesch N,McCully C,Cole DE,Godwin K,Balis FM

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:This prospective multicenter phase II study was carried out to investigate the efficacy, safety and pharmacokinetics of S-1 monotherapy in elderly patients over 75 years of age, with unresectable advanced or recurrent gastric cancer. METHODS:Patients had measurable or evaluable lesions according to the Japanes...

journal_title：Cancer chemotherapy and pharmacology

authors： Koizumi W,Akiya T,Sato A,Sakuyama T,Sasaki E,Tomidokoro T,Hamada T,Fujimori M,Kikuchi Y,Shimada K,Mine T,Yamaguchi K,Sasaki T,Kurihara M

更新日期：2010-05-01 00:00:00

abstract：PURPOSE:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are key drugs in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR activating mutations. We assessed the efficacy and safety of one EGFR tyrosine kinase inhibitor, erlotinib, in elderly Japanese patients with EGFR-mutated NSCLC....

journal_title：Cancer chemotherapy and pharmacology

authors： Inoue Y,Inui N,Asada K,Karayama M,Matsuda H,Yokomura K,Koshimizu N,Imokawa S,Yamada T,Shirai T,Kasamatsu N,Suda T

更新日期：2015-07-01 00:00:00

abstract：:In January 1983, the German Society of Pediatric Oncology started a cooperative trial (MAKEI 83) for non-testicular germ-cell tumors. The pilot phase closed in December 1985. The treatment regimen was stratified according to histology, tumor site and tumor stage. In malignant non-seminomatous germ-cell tumors (mNSGCTs...

journal_title：Cancer chemotherapy and pharmacology

authors： Gobel U,Calaminus G,Häas RJ,Jurgens H,Niethammer D,Ritter J,Spaar HJ,Harms D

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:Troxacitabine (BCH-4556, l-(-)-OddC, Troxatyl) is a novel beta- l-nucleoside analogue with potent antineoplastic activity both in vitro and in several tumor models in vivo, and is presently in phase II clinical trials. The combination of the cytosine analogues troxacitabine and araC (1-beta- d-arabinofuranosylc...

journal_title：Cancer chemotherapy and pharmacology

authors： Bouffard DY,Jolivet J,Leblond L,Hamelin B,Ouellet F,Barbeau S,Richard A,Gourdeau H

更新日期：2003-12-01 00:00:00

abstract：PURPOSE:To describe the natural growth of vestibular schwannoma in patients with neurofibromatosis type 2 and to predict tumor volume evolution in patients treated with bevacizumab and everolimus. METHODS:Clinical data, including longitudinal tumor volumes in patients treated by bevacizumab (n = 13), everolimus (n = 7...

journal_title：Cancer chemotherapy and pharmacology

authors： Ouerdani A,Goutagny S,Kalamarides M,Trocóniz IF,Ribba B

更新日期：2016-06-01 00:00:00

abstract：PURPOSE:Plitidepsin absorption, distribution, metabolism and excretion characteristics were investigated in a mass balance study, in which six patients received a 3-h intravenous infusion containing 7 mg 14C-plitidepsin with a maximum radioactivity of 100 µCi. METHODS:Blood samples were drawn and excreta were collecte...

journal_title：Cancer chemotherapy and pharmacology

authors： van Andel L,Rosing H,Tibben MM,Lucas L,Lubomirov R,Avilés P,Francesch A,Fudio S,Gebretensae A,Hillebrand MJX,Schellens JHM,Beijnen JH

更新日期：2018-09-01 00:00:00

abstract：:Copovithane is an uncharged, water-soluble, synthetic polymer with an average molecular weight of 5800 daltons. It demonstrates antitumor activity in vivo against a variety of tumors in animal models but is inactive in vitro. This agent has been found to have immunorestorative activity in man. In concert with its phas...

journal_title：Cancer chemotherapy and pharmacology

authors： Rosenblum MG,Hortobagyi GN

更新日期：1986-01-01 00:00:00

abstract：PURPOSE:Bevacizumab (BV) prolongs the survival of colorectal cancer patients when combined with irinotecan (CPT-11)-based regimens. In the AVF2107g study, the area under the curve (AUC) ratio for bolus CPT-11/5-fluorouracil (5-FU)/leucovorin (LV) (IFL) with the BV arm to bolus IFL with placebo indicated that SN-38 conc...

journal_title：Cancer chemotherapy and pharmacology

authors： Horita Y,Yamada Y,Hirashima Y,Kato K,Nakajima T,Hamaguchi T,Shimada Y

更新日期：2010-02-01 00:00:00

abstract：PURPOSE:The present study was designed to determine pharmacological and biochemical properties of 2-methoxyantimycin A analogs (OMe-A1, OMe-A2, OMe-A3, and OMe-A5), which are novel antitumor compounds, and provide a basis for future pharmaceutical development, preclinical evaluation, and clinical trials. METHODS:A hig...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang H,Li M,Rhie JK,Hockenbery DM,Covey JM,Zhang R,Hill DL

更新日期：2005-09-01 00:00:00

abstract：BACKGROUND:Ovarian cancer is one of the most frequently fatal gynecological cancers because most cases are diagnosed at an advanced stage. Loss of growth control and a marked resistance to apoptosis are considered major mechanisms driving tumor progression. Little is known about the effect of various treatment regimens...

journal_title：Cancer chemotherapy and pharmacology

authors： Dutta T,Sharma H,Kumar L,Dinda AK,Kumar S,Bhatla N,Singh N

更新日期：2005-10-01 00:00:00

abstract：:A total of 23 patients were treated at five dose escalations with high-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. The maximum tolerated doses of cyclophosphamide, cisplatin, and melphalan were 5,625, 180, and 80 mg/m2, respectively. The dose-limiting toxicity was c...

journal_title：Cancer chemotherapy and pharmacology

authors： Peters WP,Stuart A,Klotman M,Gilbert C,Jones RB,Shpall EJ,Gockerman J,Bast RC Jr,Moore JO

更新日期：1989-01-01 00:00:00

abstract：UNLABELLED:A hemopoietin with the ability to accelerate both platelet and granulocyte recovery after intensive chemotherapy would have great clinical utility. The recombinant fusion protein composed of human granulocyte-macrophage colony-stimulating factor and interleukin-3 (PIXY321), showed some promise in early adult...

journal_title：Cancer chemotherapy and pharmacology

authors： Furman WL,Rodman JH,Tonda ME,Luo X,Arnold B,Marina N,Garrison L,Hanna R,Pratt CB,Meyer WH

更新日期：1998-01-01 00:00:00

abstract：:The pharmacokinetics of pentamethylmelamine (PMM) have been investigated in mouse (Balb C-, CBA/LAC, nude), rat (Wistar), and man. In all three species, PMM was extensively demethylated to N2,N2,N4,N6-tetramethylmelamine and N2,N4,N6-trimethylmelamine, although marked species differences in the rate of metabolism were...

journal_title：Cancer chemotherapy and pharmacology

authors： Rutty CJ,Newell DR,Muindi JR,Harrap KR

更新日期：1982-01-01 00:00:00

abstract：PURPOSE:Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bose P,Perkins EB,Honeycut C,Wellons MD,Stefan T,Jacobberger JW,Kontopodis E,Beumer JH,Egorin MJ,Imamura CK,Douglas Figg W Sr,Karp JE,Koc ON,Cooper BW,Luger SM,Colevas AD,Roberts JD,Grant S

更新日期：2012-06-01 00:00:00

abstract：:A model incorporating recent information regarding the specificity of a high-performance liquid chromatographic assay for "active" platinum in plasma ultrafiltrate, and the concept of mobile and fixed metabolites, was developed for cancer patients treated with cisplatin. Model parameters were determined using plasma a...

journal_title：Cancer chemotherapy and pharmacology

authors： Reece PA,Stafford I,Russell J,Khan M,Gill PG

更新日期：1987-01-01 00:00:00

abstract：:Selective protection of the normal host tissues from the toxic effects of anticancer agents would allow the use of higher, probably more effective, doses of the drugs. It has been demonstrated that delayed high-dose uridine administration after 5-fluorouracil decreases the extent of myelosuppression and causes faster ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kralovanszky J,Prajda N,Kerpel-Fronius S,Bagrij T,Kiss E,Peters GJ

更新日期：1993-01-01 00:00:00

abstract：BACKGROUND:Recently, melatonin has been associated with cancer both in vitro and in vivo. However, the value of melatonin in the treatment of cancer remains disputable. Hence, we performed a systematic review of randomized controlled trials (RCTs) of melatonin in solid tumor cancer patients and observed its effect on t...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang YM,Jin BZ,Ai F,Duan CH,Lu YZ,Dong TF,Fu QL

更新日期：2012-05-01 00:00:00

abstract：PURPOSE:5-Fluorouracil (5-FU), an anti-cancer drug, has been used for hepatoblastoma (HB) chemotherapy in children, who may have impaired  ovarian follicle pool reserve with lasting effects to reproduction. Therefore, this study aimed to investigate 5-FU effects on survival, growth, and morphology of ovarian preantral ...

journal_title：Cancer chemotherapy and pharmacology

authors： Almeida JZ,Lima LF,Vieira LA,Maside C,Ferreira ACA,Araújo VR,Duarte ABG,Raposo RS,Báo SN,Campello CC,Oliveira LFS,da Costa TP,Abreu JG,Figueiredo JR,Oriá RB

更新日期：2021-01-20 00:00:00

abstract：:Glycoprotein (gp) 130, a receptor component for interleukin 6 (IL-6), can associate with a soluble IL-6 receptor (sIL-6R)-IL-6 complex. To examine the role of gp130 signaling in human hematopoietic progenitor-cell proliferation and differentiation, we studied the effects of the sIL-6R-IL-6 complex in combination with ...

journal_title：Cancer chemotherapy and pharmacology

authors： Nakahata T,Sui X,Tanaka R,Tajima S,Muraoka K,Ebihara Y,Tsuji K

更新日期：1996-01-01 00:00:00

abstract：:Twenty-seven patients with liver metastases from colorectal carcinoma were treated with 5-fluorouracil, adriamycin, and mitomycin C (FAM) by hepatic artery infusion (HAI) every 2-3 months for a maximum of eight courses. Median survival for all patients was 22 months. Toxicity was acceptable and consisted in severe mye...

journal_title：Cancer chemotherapy and pharmacology

authors： Wils J,Schlangen J,Naus A

更新日期：1984-01-01 00:00:00

abstract：BACKGROUND:In this phase II clinical trial, we evaluated the efficacy and safety of S-1 monotherapy in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We also measured plasma concentrations of 5-fluorouracil (5-FU) and 5-chloro-2,4-dihydroxypyridine components of S-1 and examined correlati...

journal_title：Cancer chemotherapy and pharmacology

authors： Wada M,Yamamoto M,Ryuge S,Nagashima Y,Hayashi N,Maki S,Otani S,Katono K,Takakura A,Yanaihara T,Igawa S,Yokoba M,Mitsufuji H,Kubota M,Katagiri M,Masuda N

更新日期：2012-04-01 00:00:00

abstract：:Breast cancer is presently the most predominant tumor type and the second leading cause of tumor-related deaths among women. Although advancements in diagnosis and therapeutics have momentously improved, chemoresistance remains an important challenge. Tumors oppose chemotherapeutic agents through a variety of mechanis...

journal_title：Cancer chemotherapy and pharmacology

authors： Mehraj U,Dar AH,Wani NA,Mir MA

更新日期：2021-01-09 00:00:00

abstract：PURPOSE:This phase I study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and preliminary antitumor effects of sunitinib combined with modified FOLFOX6 (mFOLFOX6). METHODS:Patients with advanced solid malignancies received mFOLFOX6 in 2-week cycles with escalating sunitinib doses (2...

journal_title：Cancer chemotherapy and pharmacology

authors： Leong S,Eckhardt SG,Chan E,Messersmith WA,Spratlin J,Camidge DR,Diab S,Khosravan R,Lin X,Chow Maneval E,Lockhart AC

更新日期：2012-07-01 00:00:00

abstract：:Experimental data suggest that multidrug resistance in cancer may be overcome by using an increased dose of anticancer agent(s) in combination with a resistance-modifying agent (RMA). We studied the pharmacokinetics and metabolism of both epirubicin (EPI) and verapamil (VPL) to explore the possible pharmacokinetic int...

journal_title：Cancer chemotherapy and pharmacology

authors： Mross K,Hamm K,Hossfeld DK

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:Cyclosporine A (CyA) is able to inhibit P-glycoprotein (P-gp) and to increase cytotoxicity of some anticancer drugs, including etoposide. However, the effect of CyA on the distribution of etoposide in normal tissues, which could affect their toxicity, has not been studied extensively. The purpose of this study ...

journal_title：Cancer chemotherapy and pharmacology

authors： Cárcel-Trullols J,Torres-Molina F,Araico A,Saadeddin A,Peris JE

更新日期：2004-08-01 00:00:00

abstract：:Adriamycin, a broad-spectrum cytotoxic agent useful in cancer chemotherapy, is limited by a dose-dependent cardiomyopathy mediated in part by disruption of mitochondrial energetics. Hexakis(2-methoxyisobutyl isonitrile)technetium(I) (99mTc-SESTAMIBI) is a gamma-emitting radiopharmaceutical with myocellular accumulatio...

journal_title：Cancer chemotherapy and pharmacology

authors： Piwnica-Worms D,Chiu ML,Kronauge JF

更新日期：1993-01-01 00:00:00